In the current study, we utilized patient <i>RB1</i> <sup>-/-</sup> retinal organoids, which model a cone-precursor-derived subtype of Rb, to evaluate the cytotoxic efficacy and selectivity of candidate therapeutics targeting these tumor-initiating cells. The gene discussed is RB1; the disease is neoplasm.